Endo International PLC (ENDP.O)

ENDP.O on Nasdaq

65.74USD
11 Jul 2014
Price Change (% chg)

$-0.56 (-0.84%)
Prev Close
$66.30
Open
$67.00
Day's High
$67.10
Day's Low
$65.42
Volume
988,785
Avg. Vol
2,439,789
52-wk High
$82.16
52-wk Low
$36.17

ENDP.O

Chart for ENDP.O

About

Endo International PLC, formerly Endo Health Solutions Inc., is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm , Opana ER, Voltaren Gel, Percocet , Frova , Supprelin LA,... (more)

Overall

Beta: 1.18
Market Cap (Mil.): $10,009.87
Shares Outstanding (Mil.): 152.26
Dividend: --
Yield (%): --

Financials

  ENDP.O Industry Sector
P/E (TTM): -- 35.37 35.77
EPS (TTM): -8.27 -- --
ROI: -16.19 19.00 18.27
ROE: -48.42 19.78 19.16
Search Stocks

FDA approves Endo International's testosterone drug

- Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

06 Mar 2014

UPDATE 1-FDA approves Endo International's testosterone drug

March 6 - Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

06 Mar 2014

FDA approves Endo Health's testosterone drug

March 6 - Endo Health Solutions Inc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone drug, Aveed, to treat male hypogonadism.

06 Mar 2014

Endo to pay $193 million over Lidoderm marketing

NEW YORK - Endo Health Solutions Inc will pay $193 million to resolve civil and criminal allegations of unlawful marketing of the pain treatment Lidoderm, the U.S. Justice Department and New York Attorney General Eric Schneiderman said Friday.

21 Feb 2014

Endo to pay $193 million over Lidoderm marketing

NEW YORK - Endo Health Solutions Inc will pay $193 million to resolve civil and criminal allegations of unlawful marketing of the pain treatment Lidoderm, the Justice Department and New York Attorney General Eric Schneiderman said Friday.

21 Feb 2014

UPDATE 1-Endo to pay $193 million over Lidoderm marketing

NEW YORK, Feb 21 - Endo Health Solutions Inc will pay $193 million to resolve civil and criminal allegations of unlawful marketing of the pain treatment Lidoderm, the U.S. Justice Department and New York Attorney General Eric Schneiderman said Friday.

21 Feb 2014

UPDATE 1-Endo to pay $193 million over Lidoderm marketing

NEW YORK, Feb 21 - Endo Health Solutions Inc agreed to pay $193 million to resolve civil and criminal allegations of unlawful marketing of the drug Lidoderm, the U.S. Justice Department and New York state Attorney General Eric Schneiderman announced on Friday.

21 Feb 2014

BRIEF-Endo to pay $173 million over Lidoderm marketing

NEW YORK, Feb 21 - Endo Health Solutions Inc agreed to pay $173 million to U.S. state and federal authorities to resolve allegations of unlawful marketing of the drug Lidoderm, New York Attorney General Eric Schneiderman said in a statement.

21 Feb 2014

NuPathe accepts Teva's takeover offer, ends deal with Endo

Jan 21 - NuPathe Inc said it terminated its takeover deal with Endo Health Solutions Inc and accepted an offer from Israel's Teva Pharmaceutical Industries Ltd .

21 Jan 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks